Galapagos NV GLPG · Stock Open Galapagos NV in new tab
Galapagos NV Analysis (GLPG)
Is Galapagos NV a good investment? Galapagos NV (GLPG) is currently trading at 27.98 USD.
In terms of valuation, the stock trades at a P/E ratio of 3.18. This relatively low multiple may signal that Galapagos NV is undervalued compared to historical market norms.
Earnings Schedule: Galapagos NV is expected to release its next earnings report on Aug. 10, 2026. The market consensus estimate for Forward EPS is -1.04.
Investor FAQ
Does Galapagos NV pay a dividend?
No, it does not currently pay a dividend.
What asset class is Galapagos NV?
Galapagos NV is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 10, 2026. The company currently has a trailing EPS of 8.71.
Company Profile
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Community Discussion